OMedLive

CME Presentations

Follicular Lymphoma


Presentations


Speakers

  • Jonathan W. Friedberg, MD, MMSc

    Jonathan W. Friedberg, MD, MMSc

    Jonathan W. Friedberg, MD, MMSc

    University of Rochester

    Jonathan W. Friedberg, MD, is professor of medicine, hematology/oncology division chief and director of the Wilmot Cancer Institute, University of Rochester Medical Center in Rochester, New York. Dr Friedberg was designated a Scholar in Clinical Research of the Leukemia & Lymphoma Society for his work on B-cell receptor signaling inhibition, and plays a leadership role in the University of Rochester SPORE in lymphoma grant. He is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin’s lymphoma. Dr Friedberg received his medical degree, as well as his MMSc degree in clinical investigation, from Harvard Medical School in Boston, Massachusetts.
  • John P. Leonard, MD

    John P. Leonard, MD

    John P. Leonard, MD

    Weill Cornell Medicine and NewYork-Presbyterian Hospital

    John P. Leonard, MD, is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology and associate dean for clinical research at Weill Cornell Medical College in New York. He is vice chairman of the Weill Department of Medicine and associate director of the Meyer Cancer Center at Weill Cornell Medical College and New York Presbyterian Hospital, where he also serves as an attending physician and director of the Joint Clinical Trials Office. His primary research interest is developing novel therapeutic strategies for the treatment of lymphoma and related hematologic malignancies. Dr Leonard is a member of the American Board of Internal Medicine subspecialty board for Hematology, and is chair of the Lymphoma Committee of the Alliance for Clinical Trials in Oncology.
  • Thomas E. Witzig, MD

    Thomas E. Witzig, MD

    Thomas E. Witzig, MD

    Professor of Medicine

    Thomas E. Witzig, MD, is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Rochester, Minnesota. He is deputy director for clinical and translational research, Mayo Clinic Cancer Center, co-PI for the University of Iowa/Mayo Clinic Lymphoma SPORE grant, and is a of professor of medicine at the Mayo Clinic College of Medicine and Science. Dr Witzig’s clinical and research interests focus on malignant lymphoma and multiple myeloma; his current focus is on agents that disrupt signal transduction pathways in cancer cells. He has been a leader in the development of radioimmunotherapy, mTOR inhibitors and immunomodulatory drugs, and has co-authored more than 500 articles, books, book chapters, letters, and more than 600 abstracts.

CME Information

Follicular Lymphoma: Best Practices in the Therapeutic Management


LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Assess optimal time to initiate treatment for FL in order to delay disease progression and maintain patient quality of life
  • Appraise evidence‐based guidelines and recommendations regarding first‐line and maintenance therapy for FL
  • Evaluate recent safety and efficacy clinical trial data for the therapeutic management of previously untreated FL

Acknowledgement

This activity is supported by an educational grant from Genentech.

Tuition

Complimentary

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

Physician Continuing Education
Live Internet Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Releasae/Expiration

Live Activity
Thursday, July 26, 2018 from 2:00pm – 3:00pm EDT.

Enduring Material
The enduring material will be available from July 26, 2018 to September 26, 2019.

Target Audience

This activity is intended for US‐based hematologist‐oncologists, medical oncologists, medical fellows, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with follicular lymphoma. Other clinicians in radiation oncology, surgery, radiology (including interventional, diagnostic, and nuclear medicine), internal medicine and primary care may also benefit from education.

Estimated Time to Complete

This activity consists of one session which should take approximately 1 hour to complete.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to www.OMedlive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Presenters

Jonathan W. Friedberg MD, MMsc
Samuel E. Durand Professor of Medicine
Director, Wilmot Cancer Institute
University of Rochester

Consulting Fees: Astellas, Bayer

John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Associate Director, Sandra and Edward Meyer Cancer Center
Executive Vice Chair, Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine

Consulting Fees: ADC Therapeutics, AstraZeneca, Celgene, Bayer, Biotest, BMS, Gilead, Genentech, Juno, Karyopharm, MEI Pharma, Novartis, Pfizer, Rohe, Sutro, United Therapeutics

Thomas E. Witzig, MD
Professor of Medicine
Division of Hematology, Department of Medicine
Mayo Clinic in Rochester, Minnesota

Consulting Fees: Sandoz

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Financial Disclosures

Anne Roc, PhD
Medical Director
PlatformQ Health Education, LLC

None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Discalimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com